Non-pharmacological interventions and symptomatic treatment with acetylcholinesterase inhibitors (AChEIs) or uncompetitive NMDA receptor antagonists have been the principal forms of fighting AD for more than two decades. The gene discussed is ACHE; the disease is Alzheimer disease.